



CRI-ENCI-AACR  
SIXTH INTERNATIONAL  
CANCER IMMUNOTHERAPY CONFERENCE

# TRANSLATING SCIENCE INTO SURVIVAL

September 28 - October 1, 2022  
New York Hilton Midtown | New York, NY

## CONFERENCE PROGRAM

(Updated as of September 29, 2022)

### TUESDAY, SEPTEMBER 27, 2022

**3:00 pm**      **Registration Opens** (3:00-7:00 pm, West Promenade)

### WEDNESDAY, SEPTEMBER 28, 2022

**7:00 am**      **Breakfast** (7:00-8:00 am, West Promenade)

**8:00 am**      **Welcome**

**Margaret Foti**, American Association for Cancer Research, Philadelphia, Pennsylvania

**Jill O'Donnell-Tormey**, Cancer Research Institute, New York, New York

**8:15 am**      **Keynote Address**

**Crystal L. Mackall**, Stanford Center for Cancer Cell Therapy, Stanford University School of Medicine, Stanford, California

Expanding the reach of CAR T cell therapy for cancer

**9:00 am-12:30 pm**

**Session 1: T Cell Failure in Cancer Immunotherapy (including Tumor-Immune Metabolic Interactions)**

**Session Chair: Andrea Schietinger**, Memorial Sloan Kettering Cancer Center, New York, New York

**9:00 am**      **Andrea Schietinger**

CD8 T cell fate decisions in cancer and autoimmunity

**9:30 am**      **Giovanni Galletti**, University of California, San Diego, La Jolla, California

TGF- $\beta$  inhibits the function of progenitor-exhausted CD8+ T cells in response to PD-1 blockade\*

**9:45 am**      **James Reading**, University College London, Cancer Institute, London, United Kingdom

Circulating Tex cells track non-small cell lung cancer evolution and predict response to immunotherapy\*

**10:00 am**      **Benjamin Youngblood**, St. Jude Children's Research Hospital, Memphis, Tennessee

Epigenetic programs regulating CD8 T cell responses during immunotherapy

**10:30 am**      **Daniela Thommen**, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Dissecting and modulating reactive anti-tumor immunity in human cancers

**11:00 am**      **Refreshment Break** (11:00-11:30 am, Americas Halls I & II)

**11:30 am**      **Dario A. Vignali**, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

LAG-3: The third checkpoint inhibitor

**12:00 pm**      **Ansuman Satpathy**, Stanford University School of Medicine, Gladstone Institute for Genomic Immunology, Stanford, California

High-throughput genomics in cancer immunotherapy

**12:30 pm**      **LUNCH AND EXHIBITS** (12:30-2:00 pm, Americas Halls I & II)

**2:00-2:30 pm**

**William B. Coley Lecture**

2:00 pm      **Feng Shao**, National Institute of Biological Sciences, Beijing, China  
Pyroptosis: From antibacterial immunity to antitumor immunity

**2:30-6:00 pm**

**Session 2: Yin and Yang of Tumor Microenvironment (part 1): Suppressing Antitumor Response**

**Session Chair: Mario Paolo Colombo**, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

2:30 pm      **Mario Paolo Colombo**

Immune function of extracellular matrix in tumor microenvironment and bone marrow

3:00 pm      **Ellen Puré**, University of Pennsylvania School of Veterinary Medicine, Philadelphia, Pennsylvania

Stromal cells and matrix direct immune cell trafficking and function in the microenvironment of pancreatic cancer

3:30 pm      **Malay Haldar**, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

Novel subsets of tumor-promoting macrophages

4:00 pm      **Arja Ray**, University of California, San Francisco, San Francisco, California

Critical role of macrophages in organizing adaptive immunity against tumors\*

4:15 pm      **Refreshment Break** (4:15-4:45 pm, Americas Halls I & II)

4:45 pm      **Mikala Egeblad**, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York

Neutrophils as drivers of metastasis - generation and function

5:15 pm      **Santosh Vardhana**, Memorial Sloan Kettering Cancer Center, New York, New York

Context-dependent regulation of T-cell exhaustion by extracellular nutrient availability

5:45 pm      **Marine Fidelle**, INSERM, Gustave Roussy Cancer Campus, Villejuif, France

Antibiotics disrupt the ileal MAdCAM-1/ $\alpha$ 4 $\beta$ 7 axis, compromising tumor immunosurveillance during PD-1 blockade\*

**6:30 pm**      **Welcome Reception** (6:30-8:30 pm, Americas Halls I & II)

**THURSDAY, SEPTEMBER 29, 2022**

7:30 am **Breakfast** (7:30-8:30 am, West Promenade)

**8:30 am-12:00 pm**

**Session 3: Yin and Yang of Tumor Microenvironment (part 2): Enhancing Antitumor Response**

**Session Chair: James P. Allison**, The University of Texas MD Anderson Cancer Center, Houston, Texas

8:30 am **Miriam Merad**, Icahn School of Medicine at Mount Sinai, New York, New York  
Molecular and spatial correlates of response to PD-1 blockade in human tumors

9:00 am **Stefani Spranger**, MIT, Cambridge, Massachusetts  
Not all anti-tumor T cell responses are equal: Why dendritic cells matter

9:30 am **Brian Ruffell**, Moffitt Cancer Center, Tampa, Florida  
Therapeutic targeting of intratumoral dendritic cells

10:00 am **Tullia C. Bruno**, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania  
Harnessing B cell and tertiary lymphoid structure function in ovarian cancer for improved anti-tumor immunity

10:30 am **Refreshment Break** (10:30-11:00 am, Americas Halls I & II)

11:00 am **Ilkka Pietilä**, Uppsala University, Uppsala, Sweden  
Mechanisms regulating tertiary lymphoid structures in the CNS\*

11:15 am **Min-Hee Oh**, Yale University, New Haven, Connecticut  
Identifying the role of tRNA modifications in T cells\*

11:30 am **Aaron Ring**, Yale School of Medicine, New Haven, Connecticut  
Overcoming resistance to cytokine activity in the TME

**12:00 pm LUNCH and POSTER SESSION A and EXHIBITS** (12:00-2:00 pm, Americas Halls I & II)

**2:00-3:45 pm**

**Session 4: The Immunology of Lesional Heterogeneity of Minimal Residual Disease**

**Session Chair: Guido Kroemer**, Centre de Recherche des Cordeliers, Paris, France

2:00 pm **Brian Topp**, Merck, Kenilworth, New Jersey  
Lesion-to-lesion heterogeneity in response to Pembrolizumab treatment

2:30 pm **Matteo Gentili**, Broad Institute of MIT and Harvard, Cambridge, Massachusetts  
ESCRT-dependent STING degradation curtails steady-state and cGAMP-induced signaling\*

2:45 pm **James Ross**, Emory University, Atlanta, Georgia  
Role of XCR1+ dendritic cells in the generation and maintenance of stem like CD8 T cells\*

3:00 pm **Jose M. Adrover**, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York  
A vascular-restricted, tumor-induced neutrophil population drives vascular occlusion, pleomorphic necrosis, and metastasis\*

3:15 pm **Valsamo Anagnostou**, Johns Hopkins University School of Medicine, Baltimore, Maryland  
Liquid biopsy approaches for monitoring immunotherapy response

3:45 pm **Refreshment Break** (3:45-4:15 pm, Americas Halls I & II)

4:15-5:15 pm

**Session 5: Moderated Debate-Utility of Preclinical Models**

**Moderator: Miriam Merad**, Icahn School of Medicine at Mount Sinai, New York, New York

4:15 pm

*Mouse perspective:*

**Nikhil S. Joshi**, Yale School of Medicine, New Haven, Connecticut

Investigating mechanisms for maintaining functional immune responses in developing tumors

**Michelle Krogsgaard**, Perlmutter Cancer Center at NYU School of Medicine, New York, New York

Preclinical mouse models for T cell-based immunotherapies

*Clinical perspective:*

**Padmanee Sharma**, The University of Texas MD Anderson Cancer Center, Houston, Texas

From the clinic to the lab: Investigating mechanisms of response and resistance to immune checkpoint therapy

**Dmitriy Zamarin**, Memorial Sloan Kettering Cancer Center, New York, New York

Modeling immune response in ovarian cancer: opportunities and challenges

**FRIDAY, SEPTEMBER 30, 2022**

7:30 am

**Breakfast** (7:30-8:30 am, West Promenade)

8:30 am-12:15 pm

**Session 6: Cellular Therapies: Engineering T cells**

**Session Chair: Yvonne Y. Chen**, University of California, Los Angeles, Los Angeles, California

8:30 am

**Christopher A. Klebanoff**, Memorial Sloan Kettering Cancer Center, New York, New York

Immunogenic and therapeutic landscape of NRAS 61 public neoantigens

9:00 am

**Marcelo Vailati Negro**, The University of Texas MD Anderson Cancer Center, Houston, Texas

Objective clinical response by KRAS mutation-specific TCR-T cell therapy in previously treated advanced non-small cell lung cancer\*

9:15 am

**Johanna Olweus**, University of Oslo, Oslo, Norway

A TCR targeting a shared mutation mediates eradication of AML *in vivo*\*

9:30 am

**Yvonne Y. Chen**

Engineering next-generation CAR-T cells for cancer immunotherapy

10:00 am

**Avery Posey**, University of Pennsylvania, Philadelphia, Pennsylvania

Leveraging tumor-associated alterations in O-glycosylation for cancer immunotherapy

10:30 am

**Refreshment Break** (10:30-11:00 am, Americas Halls I & II)

11:00 am

**Ugur Sahin**, BioNTech RNA Pharmaceuticals GmbH, Mainz, Germany

In vivo augmented T cell therapies

11:30 am

**Jorge Mansilla-Soto**, Memorial Sloan Kettering Cancer Center, New York, New York

12:00 pm

**Sam Saibil**, Princess Margaret Cancer Centre, Toronto, Canada

Amino acid starvation response enhances oxidative metabolism and T cell anti-tumor activity\*

12:15 pm

**LUNCH and POSTER SESSION B and EXHIBITS** (12:15-2:15 pm, Americas Halls I & II)

**2:15-5:15 pm**

**Session 7: Embracing the Host Ecosystem or Ecology: Immune Health and Fitness**

**Session Chair: E. John Wherry**, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

- 2:15 pm **E. John Wherry**  
Role of immune health in cancer immunotherapy and beyond: lessons from COVID-19
- 2:45 pm **Jennifer Wargo**, The University of Texas MD Anderson Cancer Center, Houston, Texas  
Modulating the microbiome to promote health and end cancer
- 3:15 pm **Laurence Zitvogel**, Gustave Roussy, Paris, France  
The gut checkpoint inhibitors
- 3:45 pm **Refreshment Break** (3:45-4:15 pm, Americas Halls I & II)
- 4:15 pm **Shelley Herbrich**, The University of Texas MD Anderson Cancer Center, Houston, Texas  
Impact of Tet2-mutant clonal hematopoiesis on solid tumor immunology and response to checkpoint blockade\*
- 4:30 pm **Matthew H. Spitzer**, University of California, San Francisco, Gladstone-UCSF Institute for Genomic Immunology, San Francisco, California  
Systemic impacts of cancer on immune function
- 5:00 pm **Jeremy Goc**, Weill Cornell Medicine, New York, New York  
Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer\*

**SATURDAY, OCTOBER 1, 2022**

7:00 am **Breakfast** (7:00-8:00 am, West Promenade)

**8:00-10:15 am**

**Session 8: Barriers and Opportunities for Tumor Vaccination**

**Session Chair: Ellen Puré**, University of Pennsylvania School of Veterinary Medicine, Philadelphia, Pennsylvania

- 8:00 am **Vinod Balachandran**, Memorial Sloan Kettering Cancer Center, New York, New York  
Individualized mRNA neoantigen vaccines for pancreatic cancer
- 8:30 am **Sandra Demaria**, Weill Cornell Medicine, New York, New York  
Antigen presentation by irradiated cancer cells
- 9:00 am **Justin Gibson**, Genentech, South San Francisco, California  
Identifying and overcoming barriers that limit the therapeutic anti-tumor efficacy of individualized RNA-lipoplex vaccines\*
- 9:15 am **Joshua Brody**, Icahn School of Medicine at Mount Sinai, New York, New York  
In situ vaccination: Large tumor regressions, off the shelf
- 9:45 am **Ferry A. Ossendorp**, Leiden University Medical Center, Leiden, The Netherlands  
Self adjuvanted peptide-based cancer vaccines
- 10:15 am **Refreshment Break** (10:15-10:30 am, West Promenade)

**10:30 am-1:00 pm**

**Session 9: Spatial, Temporal and Computational Approaches for Understanding Tumor Immunity**

**Session Chair: Robert D. Schreiber**, Washington University in St. Louis, St. Louis, Missouri

- 10:30 am **Haydn T. Kissick**, Emory University School of Medicine, Atlanta, Georgia  
CD8 T-cell activation in cancer is comprised of two distinct phases.
- 11:00 pm **Benjamin G. Vincent**, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina  
Cancer immunogenomics research with the CRI iAtlas web portal
- 11:30 am **Ronald N. Germain**, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland  
Gaining Insight into Tumor Immunity By Combining New Highly Multiplex 2D and 3D Imaging with Analytical Tools
- 12:00 pm **Assaf Magen**, Icahn School of Medicine at Mount Sinai, New York, New York  
Intratumoral mregDC and CXCL13 T helper niches enable local differentiation of CD8 T cells following PD-1 blockade\*
- 12:15 am **Robert D. Schreiber**, Washington University in St. Louis, St. Louis, Missouri  
Spatial-proteomics analysis of successful cancer immunotherapy in a mouse cancer model
- 12:45 pm **Closing Remarks**

*\*Proffered presentations from selected abstracts*